Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

Sponsor
Rebiscan, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01832883
Collaborator
Vanderbilt University (Other)
78
1
19
4.1

Study Details

Study Description

Brief Summary

The purpose of this project is to compare the performance of the Pediatric Vision Scanner (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at detecting amblyopia and strabismus.

Condition or Disease Intervention/Treatment Phase
  • Device: Pediatric Vision Scanner

Study Design

Study Type:
Observational
Actual Enrollment :
78 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Pediatric Vision Scanner 4 (PVS4)
Study Start Date :
Dec 1, 2010
Actual Primary Completion Date :
Jul 1, 2012
Actual Study Completion Date :
Jul 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Normal Controls

Structurally normal eye with equal visual acuity and normal stereopsis.

Device: Pediatric Vision Scanner
Subject is scanned with a 2.5 second pediatric vision scanner device test.

Referral required

Diagnosed with amblyopia or constant strabismus, categorized based on the GSE. Amblyopia: VA <20/40 and 2 logMAR lines difference in normal eye Mild amblyopia (>20/40) Moderate amblyopia (20/40 and <20/100) Severe amblyopia (≥20/100 or worse) Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism. Strabismus: Constant: >2 PD at near and or distance. Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position. Amblyogenic factor categorization: 'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes. 'hypermetropia' (≥3.5 D), 'myopia' (≥-4.0 D), 'astigmatism' (≥1.5 D). 'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse.

Device: Pediatric Vision Scanner
Subject is scanned with a 2.5 second pediatric vision scanner device test.

Borderline

(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.

Device: Pediatric Vision Scanner
Subject is scanned with a 2.5 second pediatric vision scanner device test.

Outcome Measures

Primary Outcome Measures

  1. Binocularity score [Day 1]

Secondary Outcome Measures

  1. Presence of amblyopia risk factors [Day 1]

    'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes. 'hypermetropia' (≥3.5 D), 'myopia' (≥-4.0 D), 'astigmatism' (≥1.5 D). 'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse.

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 8 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Children aged 3-8 years

  • Signed Informed consent by parent or guardian

  • Meet all inclusion criteria.

Exclusion Criteria:
  • Children with a history of developmental delay or cognitive deficit

  • Children unable to complete the GSE (including visual acuity testing)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vanderbilt Eye Institute Nashville Tennessee United States 37232

Sponsors and Collaborators

  • Rebiscan, Inc.
  • Vanderbilt University

Investigators

  • Principal Investigator: Sean Donahue, MD, PhD, Vanderbilt Eye Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Rebiscan, Inc.
ClinicalTrials.gov Identifier:
NCT01832883
Other Study ID Numbers:
  • rebiscan-002
First Posted:
Apr 16, 2013
Last Update Posted:
Apr 13, 2018
Last Verified:
Apr 1, 2018
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 13, 2018